Tarsus Pharmaceuticals, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023; balance-sheet comparisons are with December 31, 2022. The company is a clinical-stage biopharmaceutical business developing therapeutics, led by TP-03 for Demodex blepharitis. It had no product sales; reported revenue came from its China out-license.
Key financial metrics
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| License and collaboration revenue | $2.5 million | $0.5 million |
| Research and development expense | $12.4 million | $12.1 million |
| General and administrative expense | $15.1 million | $7.9 million |
| Total operating expenses | $27.5 million | $20.1 million |
| Operating loss | $25.0 million | $19.5 million |
| Net loss | $23.4 million | $20.2 million |
| Basic and diluted loss per share | $0.88 | $0.98 |
| Net cash used in operating activities | $22.0 million | $15.3 million |
As of March 31, cash and cash equivalents were $66.0 million and marketable securities were $135.2 million, totaling approximately $201.2 million. Current assets were $208.6 million and current liabilities $13.3 million. Term-loan principal was $25.0 million ($24.5 million carrying value, net). The filing does not provide a meaningful product gross margin; the company had no product sales.
Material changes and cash flows
- Revenue increased mainly because a $2.5 million China out-license milestone was recognized in February; the cash was received in Q2 2023.
- G&A expense rose $7.2 million, primarily from added corporate and commercial-launch personnel and market research. R&D was nearly flat overall: increased TP-05 spending and a $1.0 million Elanco milestone were largely offset by lower TP-03 trial costs.
- Net loss increased $3.2 million, despite higher revenue and $2.3 million of interest income. Operating cash use rose to $22.0 million. Investing activities provided $11.3 million, mainly from net maturities of marketable securities; financing provided $5.0 million from a term-loan draw. Cash and cash equivalents fell $5.7 million during the quarter.
Outlook, risks, and unusual items
- Management estimated existing capital resources would fund planned operating expenses for at least 12 months from the May 9, 2023 filing date. It expects continued operating losses and may need additional capital; the runway depends on spending, revenue, and debt availability.
- TP-03’s FDA decision date was August 25, 2023. The company was preparing for a potential U.S. commercial launch in the second half of 2023 and expected TP-03 MGD and TP-05 Lyme-disease trial data in the second half of 2023. These are forward-looking expectations, not guaranteed outcomes.
- The credit facility had up to $130 million of remaining, tranched availability, subject to conditions and expiry dates. Its floating rate was the greater of prime plus 4.45% (capped at 11.45%) or 8.45%; the company had drawn $25 million at quarter-end. Interest-only payments were scheduled through February 2026, with principal amortization thereafter unless extended under the agreement.
- The company reported no product revenue and depends on successful clinical development, regulatory approval, commercialization, and/or further financing. Failure to obtain funding could require it to delay or reduce programs or license product rights. Clinical, regulatory, market-acceptance, competition, and macroeconomic risks remain significant.
- After quarter-end, the former CFO’s separation agreement provided for nine months of base salary severance, continued benefits, a performance-adjusted bonus payment, and accelerated vesting of options on 40,744 shares. The filing also says the company believed it had no loss exposure from SVB’s receivership after the bank’s obligations transferred to First Citizens Bank.
Most important facts for investors to verify
- FDA’s August 25, 2023 decision on TP-03 and any resulting launch timing, costs, and market uptake.
- Actual operating cash burn and whether the stated 12-month runway assumptions remain valid.
- Availability and conditions of the remaining credit tranches, including applicable draw deadlines and interest costs.
- Progress and results of the expected MGD, rosacea, and Lyme-disease clinical milestones, and the timing and collectability of China out-license payments.
- Commercial spending, dilution from equity awards or future financing, and the financial effects of the CFO transition.